Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza virus vaccine quadrivalent - Sinovac Biotech

Next Previous
Drug Profile

Influenza virus vaccine quadrivalent - Sinovac Biotech

Alternative Names: QIV- Sinovac Biotech; Quadrivalent influenza vaccine - Sinovac Biotech; Sinovac-QIV

Latest Information Update: 13 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sinovac Biotech
  • Developer Pontifical Catholic University of Chile; Sinovac Biotech
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 07 Oct 2025 Sinovac Biotech plans to initiate a phase III trial for Influenza virus infections (Prevention, In volunteers, In adults) in Philippines (Parenteral) (NCT07211152)
  • 23 May 2024 Sinovac Biotech completes a phase III trial for Influenza (Prevention, In infants, In children) in China (IM) (NCT06049927)
  • 16 Sep 2023 Sinovac Biotech initiates a phase III trial for Influenza (Prevention, In infants, In children) in China (IM) (NCT06049927)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top